Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2021, Vol. 48 Issue (2): 245-252    DOI: 10.31083/j.ceog.2021.02.2265
Systematic Review Previous articles | Next articles
Matrix metalloproteinase 9 gene promoter region -1562 C/T single nucleotide polymorphism increases the susceptibility to hypertensive disorders of pregnancy: a meta-analysis
Yi Zhou1, Ran Wang2, Shi-Xian Chen2, Li-Sheng Wu2, 3, *(), Jun-Qing Zhu2, *()
1Department of Obstetrics, Guangdong Women and Children Hospital, 510510 Guangzhou, Guangdong, China
2Department of Rheumatic & TCM Medical Center, Nanfang Hospital, Southern Medical University, 510510 Guangzhou, Guangdong, China
3Department of Internal Medicine of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Southern Medical University, 510510 Guangzhou, Guangdong, China
Download:  PDF(1693KB)  ( 72 ) Full text   ( 4 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Hypertensive disorders of pregnancy (HDP) encompass a group of diseases. Single nucleotide polymorphisms (SNPs) are common in the matrix metalloproteinase 9 (MMP9) genes. The objective of this study was to analyse whether genetic polymorphisms in MMP9-1562 C/T alter the risk of HDP. Studies published up to October 2019 across PubMed, ScienceDirect, SpringerLink, and China National Knowledge Infrastructure database were searched. Case-control or cohort studies involving subtypes of HDP and distribution of genotypes and/or alleles within MMP9-1562 C/T in both patients and controls were selected. Number of genotypes and/or alleles for MMP9-1562 C/T polymorphisms were obtained and analyzed using Stata software. Eight published reports including 1300 HDP patients and 1612 controls were included in the meta-analysis. Results showed that a variant genotype and allele of MMP9-1562 C/T increased the risk of HDP, with pooled OR 1.50 (95% CI 1.16–1.95, P = 0.002) and 1.36 (95% CI 1.15–1.61, P < 0.001). Subgroup analyses showed that the variant genotype and allele of MMP9-1562 C/T also had increased risk of preeclampsia (OR = 1.48, 1.32; 95% CI 1.18–1.86, 1.08–1.62; P = 0.001, 0.007) and gestational hypertension (OR = 2.23, 1.88; 95% CI 1.52–3.28, 1.33–2.65; P < 0.001, < 0.001) in the fixed-effects models. This suggests that variant genotype (TT + TC) and allele (T) of MMP9-1562 C/T are associated with susceptibility of HDP, especially preeclampsia and gestational hypertension.
Key words:  Hypertensive disorders of pregnancy      Gestational hypertension      Preeclampsia      Matrix metalloproteinase 9      Single nucleotide polymorphism     
Submitted:  20 August 2020      Revised:  03 November 2020      Accepted:  16 November 2020      Published:  15 April 2021     
Fund: 
81803932/Natural Science Foundation of China
2018030310025/Natural Science Foundation of Guangdong Province
2017A030313868/Natural Science Foundation of Guangdong Province
2017Z020 and 2016C024/President Foundation of Nanfang Hospital, Southern Medical University
*Corresponding Author(s):  jqzhujq@yeah.net (Jun-Qing Zhu); wlslu@smu.edu.cn (Li-Sheng Wu)   

Cite this article: 

Yi Zhou, Ran Wang, Shi-Xian Chen, Li-Sheng Wu, Jun-Qing Zhu. Matrix metalloproteinase 9 gene promoter region -1562 C/T single nucleotide polymorphism increases the susceptibility to hypertensive disorders of pregnancy: a meta-analysis. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 245-252.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog.2021.02.2265     OR     https://ceog.imrpress.com/EN/Y2021/V48/I2/245

[1] Jing Wang, Min Zhou, Li Zhang, Long-Xin Zhang. Effective doses 50% and 95% of subarachnoid injection of sufentanil with ropivacaine in lumbar anesthesia for cesarean section in severe preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 105-109.
[2] R. Mihăilă. Coagulation challenges in pregnancy: from thrombophilia involvement and management to the utility of thrombin generation monitoring[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 814-820.
[3] H.M. Kim, Y.S. Choo, W.J. Seong. Serum NT-proBNP levels as a marker for cardiopulmonary function in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 511-515.
[4] H. Yolli, M.E. Demir, R. Yildizhan. Neutrophil gelatinase associated lipocalin-2 (Ngal) levels in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 519-523.
[5] A. E. Kholeif, M. Y. Khamis, S. Eltabakh, R. S. Swilam, A. Elhabashy, R. EISherif. Prediction of severity of preeclampsia in Egyptian patients: role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and C-reactive protein[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 183-188.
[6] J. Yoon Park, S.W. Lee, K.J. Oh, J.-S. Hong. High mean blood pressure during the first trimester is predictive of future preeclampsia development in healthy pregnant women: a cohort study in Korea[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 770-775.
[7] M. Trisovic, O. Mladenovic, J. Bila, K. Lalić, D. Kisic Tepavcevic. The predictive value of metabolic syndrome in the evaluation of pregnancy course and outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 776-778.
[8] Y. E. Purut, E. E. Buyukbayrak, F. Ercan, A. Orcun, M. Menke, A. Y. Karageyim Karsidag. Do first trimester maternal serum follistatin like 3 levels predict preeclampsia and/or related adverse pregnancy outcomes?[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 195-200.
[9] E. Ertekin, Ö. Tunçyürek, S. Kafkas, Y. Özsunar. Does the placental strain ratio correlate with the umbilical artery Doppler values?[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 227-230.
[10] A. Simsek, S. Uludag, A. Tuten, A. S. Acikgoz, S. Uludag. Maternal and perinatal outcomes in early onset and late onset preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 837-841.
[11] B. Dullaert, S. Schroven, Y. Jacquemyn. The effect of maternal vitamin D status on pregnancy outcome and child health in the first year of life[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 677-681.
[12] Jinqi Ma, Hua Yao. Persistent hypertension post-preeclampsia: a tertiary care centre-based study in China[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 741-744.
[13] R. Einikytė, A. Dapkeviciute, V. Dzenkeviciute, S. Kasnauskiene, V. Sapoka, D. Ramasauskaite. The importance of angiogenic and antiangiogenic biomarkers in pathogenesis and early diagnosis of preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 485-492.
[14] H. Kobayashi, T. Tsunemi, J. Akasaka, N. Koike, A. Shigemitsu. F. Ito, Y. Yamada, E. Fujii. Preeclampsia as a parental epigenetic disease[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 493-502.
[15] A. Jafari, S. Parchami, S. Reiisi, S. Miraj. Association of plasma homocysteine, folic acid levels, and C677T polymorphism in methylene tetra hydrofolate reductase with risk of preeclampsia: a case-control study in Iranian women[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(3): 367-374.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] Sandeep K. Krishnan, Norman E. Lepor. Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management[J]. Reviews in Cardiovascular Medicine, 2016, 17(S1): 9 -21 .
[3] Peter Shalit. Management of Dyslipidemia in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 38 -46 .
[4] Sophie Mavrogeni, Fabrizio Cantini, Gerald M. Pohost. Systemic Vasculitis: An Underestimated Cause of Heart Failure—Assessment by Cardiovascular Magnetic Resonance[J]. Reviews in Cardiovascular Medicine, 2013, 14(1): 49 -55 .
[5] Jeffrey W. Moses, Stephane Carlier, Issam Moussa. Lesion Preparation Prior to Stenting[J]. Reviews in Cardiovascular Medicine, 2004, 5(S2): 16 -21 .
[6] Dean J. Kereiakes. Coronary Small-Vessel Stenting in the Era of Drug Elution[J]. Reviews in Cardiovascular Medicine, 2004, 5(S2): 34 -45 .
[7] Michael A. Weber. The Effects on Dementia of Long-Term Treatment of Hypertension[J]. Reviews in Cardiovascular Medicine, 2003, 4(3): 197 -198 .
[8] Steven V. Edelman. The Role of the Thiazolidinediones in the Practical Management of Patients With Type 2 Diabetes and Cardiovascular Risk Factors[J]. Reviews in Cardiovascular Medicine, 2003, 4(S6): 29 -37 .
[9] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[10] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .